[Trial Data] REDEFINE 1 — what cagri adds on top of sema
REDEFINE 1 — what cagri adds on top of sema. It is the sort of thing everyone half-believes and nobody writes down. Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently. Bought small deliberately because the evidence base is thin. That felt like the only…
Disagree — you are quoting a combination arm as though it were monotherapy. Those are different results.
[removed by moderator]
Which receptor family are you attributing that effect to?
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
the interesting data is the combination, not the monotherapy
Disagree — you are quoting a combination arm as though it were monotherapy.
Agreed, and the combination arms are where the interesting numbers actually live.
Agreed, and the combination arms are where the interesting numbers actually live.
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
Which trial and which readout?
nothing containing this is approved as a standalone product